The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world. In addition to initiating Phase 3 clinical trials for VYVANSE as adjunctive therapy in Major Depressive Disorder (MDD), we're releasing highlights of exploratory data showing that cognition and executive function were improved in patients with MDD taking VYVANSE as adjunctive therapy. We've also released positive new clinical data related to our Phase 3 European ADHD clinical program. Overall, we've increased investment in our R&D programs by 21% compared to Q3 2010, and still generated good earnings growth and strong cashflows.
Over the course of the year we've seen market expectations for Shire's 2011 earnings rise, with further increases in the last quarter. After these good third quarter results, and after taking account of the lower royalty income that we will be recording in future periods, we remain on track to meet these increased expectations. We anticipate that this will be another very good year for Shire as we deliver strong sales and continue our investment program for sustained future growth."
Third Quarter 2011 Unaudited Results
Q3 2011 Q3 2010 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Total revenues 1,086 - 1,086 874 - 874 Operating income 255 86 341 156 142 298 Diluted earnings per ADS $1.02 $0.26 $1.28 $0.52 $0.64 $1.16
|SOURCE Shire plc|
Copyright©2010 PR Newswire.
All rights reserved